We have detected that you are using Internet Explorer to visit this website. Internet Explorer is now being phased out by Microsoft. As a result, NHS Digital no longer supports any version of Internet Explorer for our web-based products, as it involves considerable extra effort and expense, which cannot be justified from public funds. Some features on this site will not work. You should use a modern browser such as Edge, Chrome, Firefox, or Safari. If you have difficulty installing or accessing a different browser, contact your IT support team.
Medicines spend and use data discovery data collections Data Provision Notice
National health and care organisations require access to good quality, national data, about NHS medicine spend and use to improve patient care and outcomes, understand the medicines market and manage medicines spend. Discovery work is required to collect and analyse data from NHS providers who have agreed to participate, to work towards an eventual common specification or standard, for data collection.
However please see note below about interruption of this work due to COVID-19.
Scope of the collection
The collection and analysis of medicines data, will enable information to be obtained about the spend and usage of medicines, by NHS providers commonly referred to as secondary care, and may include but may not be limited to:
- NHS acute providers (providing largely hospital-based services)
- NHS community providers (providing services such as district nursing, health visiting)
- NHS mental health providers
- NHS specialist providers (providing services such as specialist eyecare or cancer treatment)
- NHS ambulance services
- organisations commissioned by the NHS to provide NHS services, including medicines supply and medicines stock control services.
Legal basis for the process of data
Under section 259 of the Health and Social Care Act 2012.
Collection
The collection period starts from the date of publication of this Data Provision Notice (DPN). Due to the discovery nature of this work, data collections will be on an ad hoc basis and will be agreed between NHS Digital and those NHS providers who have agreed to participate. This DPN will be reviewed before the end of March 2021.
April 2020: Update: Note that the work to establish a secondary care medicines data collection from pharmacy stock control has been paused. This decision has been taken in response to the national Covid-19 emergency and the consequent need for NHS Digital, and other NHS bodies including trusts and their system suppliers, to prioritise work accordingly. Stakeholders involved in this work will be contacted as and when this work is resumed.
NHS providers who have agreed to participate in discovery work
This list will be updated as and when further providers agree to participate.
ODS code | Provider name |
---|---|
RJR | Countess of Chester Hospital NHS Foundation Trust |
RJZ | King's College Hospital NHS Foundation Trust |
R0A | Manchester University NHS Foundation Trust |
RBK | Walsall Healthcare NHS Trust |
Read the Data Provision Notice
Further information
-
internal Medicines spend and use data discovery Directions 2019
A Direction given by the Secretary of State for Health requiring NHS Digital to establish a collection of medicines spend and use data.